# A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Clinical trial · AstraZeneca

- Archive id: nct:NCT07221253
- Published: 2025-10-27
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07221253
- Source URL: https://clinicaltrials.gov/study/NCT07221253
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: AB02
- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1100
- sponsor: AstraZeneca
- conditions: Biliary Tract Cancer
- interventions: DRUG: Rilvegostomig; DRUG: Durvalumab; DRUG: Gemcitabine/Cisplatin
- start date: 2025-12-04
- start date type: ACTUAL
- primary completion date: 2029-07-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.